Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS) - The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects - The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Secondary Progressive Multiple Sclerosis (SPMS) Overview 9 Therapeutics Development 10 Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview 10 Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies 11 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies 16 Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development 17 AB Science SA 17 Actelion Ltd 18 Biogen, Inc. 19 Daval International Limited 20 Genzyme Corporation 21 Immune Response BioPharma, Inc. 22 Innate Immunotherapeutics Ltd 23 Kyorin Pharmaceutical Co., Ltd. 24 Mallinckrodt Plc 25 MedDay 26 MedImmune, LLC 27 Merck KGaA 28 Novartis AG 29 Opexa Therapeutics, Inc. 30 Xenetic Biosciences (UK) Limited 31 Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 Aimspro - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ApE - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 biotin - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 DC-TAB - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 GZ-402668 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 ibudilast - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 imilecleucel-t - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 inebilizumab - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 interferon beta-1b - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 IR-902 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 M-2736 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 masitinib - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 methoxsalen - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 MIS-416 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 MyeloXen - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 opicinumab - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 OSX-110 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 ponesimod - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 siponimod - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Secondary Progressive Multiple Sclerosis (SPMS) - Recent Pipeline Updates 79 Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects 105 Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products 106 Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones 107 Featured News & Press Releases 107 Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 107 Oct 06, 2015: Opexa Announces Granting of New T-cell Patents Covering Tcelna; Patent Estate Increases to 160 Issued Patents 108 Aug 06, 2015: Medical Need Europe appoints Durbin as latest distribution partner 108 Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 109 Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 109 Oct 07, 2014: Update on Innate's Phase 2B trial and other recent activities 110 Aug 19, 2014: Innate's Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval 110 Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis 111 Jun 18, 2014: Compassionate Use Programme Update 111 May 13, 2014: Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis 112 Appendix 114 Methodology 114 Coverage 114 Secondary Research 114 Primary Research 114 Expert Panel Validation 114 Contact Us 114 Disclaimer 115
List of Tables
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by AB Science SA, H1 2016 17 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Actelion Ltd, H1 2016 18 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Biogen, Inc., H1 2016 19 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Daval International Limited, H1 2016 20 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Genzyme Corporation, H1 2016 21 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Immune Response BioPharma, Inc., H1 2016 22 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Innate Immunotherapeutics Ltd, H1 2016 23 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 24 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Mallinckrodt Plc, H1 2016 25 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedDay, H1 2016 26 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedImmune, LLC, H1 2016 27 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Merck KGaA, H1 2016 28 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Novartis AG, H1 2016 29 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Opexa Therapeutics, Inc., H1 2016 30 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Number of Products by Stage and Target, H1 2016 34 Number of Products by Stage and Mechanism of Action, H1 2016 36 Number of Products by Stage and Route of Administration, H1 2016 38 Number of Products by Stage and Molecule Type, H1 2016 40 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Recent Pipeline Updates, H1 2016 79 Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects, H1 2016 105 Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products, H1 2016 106
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.